Activation of PPAR-α attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis and mitochondrial injury via upregulating 14-3-3η

This study aimed to explore the effects of Peroxisome Proliferator-activated Receptor α (PPAR-α), a known inhibitor of Ferroptosis, in Myocardial ischemia/reperfusion injury (MIRI) and its related mechanisms. In vivo and in vitro MIRI models were established. Our results showed that activation of PPAR-α decreased the size of the myocardial infarct, maintained cardiac function, and decreased the serum contents of creatine kinase-MB (CK-MB), Lactate Dehydrogenase (LDH), and Fe²⁺ in ischemia/reperfusion (I/R)-treated mice. Additionally, the results of H&E staining, DHE staining, TUNEL staining, and transmission electron microscopy demonstrated that activation of PPAR-α inhibited MIRI-induced heart tissue and mitochondrial damage. It was also found that activation of PPAR-α attenuated MIRI-induced Ferroptosis as shown by a reduction in malondialdehyde, total iron, and Reactive Oxygen Species (ROS). In vitro experiments showed that intracellular contents of malondialdehyde, total iron, LDH, Reactive Oxygen Species (ROS), lipid ROS, oxidized glutathione disulphide (GSSG), and Fe²⁺ were reduced by the activation of PPAR-α in H9c2 cells treated with anoxia/reoxygenation (A/R), while the cell viability and GSH were increased after PPAR-α activation. Additionally, changes in protein levels of the Ferroptosis marker further confirmed the beneficial effects of PPAR-α activation on MIRI-induced Ferroptosis. Moreover, the results of immunofluorescence and dual-luciferase reporter assay revealed that PPAR-α achieved its activity via binding to the 14-3-3η promoter, promoting its expression level. Moreover, the cardioprotective effects of PPAR-α could be canceled by pAd/14-3-3η-shRNA or Compound C11 (14-3-3η inhibitor). In conclusion, our results indicated that Ferroptosis plays a key role in aggravating MIRI, and PPAR-α/14-3-3η pathway-mediated Ferroptosis and mitochondrial injury might be an effective therapeutic target against MIRI.

14-3-3η; Cardioprotection; Ferroptosis; Myocardial ischemia/reperfusion injury; PPAR-α.